ReviewDrugs2000
Newer anticonvulsants: comparative review of drug interactions and adverse effects.
Review in Drugs, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 97 citations in OpenAlex.
- Levetiracetam therapy in patients with brain tumour and epilepsy.Journal of neuro-oncology · 2006Trial
- NF1 mutation-driven neuronal hyperexcitability sets a threshold for tumorigenesis and therapeutic targeting of murine optic glioma.Neuro-oncology · 2024Article
- Chromanone-A Prerogative Therapeutic Scaffold: An Overview.Arabian journal for science and engineering · 2022Review
- Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma.Journal of neuro-oncology · 2018Article
- Safety profile of lamotrigine in overdose.Therapeutic advances in psychopharmacology · 2016Review
- Preliminary anticonvulsant and toxicity screening of substituted benzylidenehydrazinyl-N-(6-substituted benzo[d]thiazol-2-yl)propanamides.TheScientificWorldJournal · 2014Article
- Management of pain in the elderly at the end of life.Drugs & aging · 2012Review
- Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development.Pharmaceuticals (Basel, Switzerland) · 2010Review
- Oxcarbazepine-induced tardive dyskinesia: A rare adverse reaction.Journal of pediatric neurosciences · 2010Article
- Basal ganglia neuroprotection with anticonvulsants after energy stress: a comparative study.Metabolic brain disease · 2009Article
- Does oxcarbazepine warrant therapeutic drug monitoring? A critical review.Clinical pharmacokinetics · 2008Review
- Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control.Experimental neurology · 2007Article
- Use and safety profile of antiepileptic drugs in Italy.European journal of clinical pharmacology · 2007Article
- Acute drug prescribing to children on chronic antiepilepsy therapy and the potential for adverse drug interactions in primary care.British journal of clinical pharmacology · 2005Article
- Clinical pharmacokinetics of oxcarbazepine.Clinical pharmacokinetics · 2003Review
- Teratogenic potential of the newer antiepileptic drugs: what is known and how should this influence prescribing?CNS drugs · 2002Review
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tolerability and drug interaction profiles of 6 new anticonvulsants: oxcarbazepine, vigabatrin, lamotrigine, gabapentin, tiagabine and topiramate, are reviewed. In general, these new anticonvulsants are well tolerated and drug interaction problems are minor with the exception of the risk of failure of oral contraceptives during treatment with oxcarbazepine or topiramate. In this review, the clinical implications of the tolerability of these drugs are discussed for different patient groups. The choice of which new anticonvulsant for which patient depends upon individual factors, in particular, seizure type, tolerability and practical administration factors. Treating elderly patients may be complicated by an increased sensitivity to adverse effects as these patients very often receive polytherapy for accompanying diseases. Drugs with very simple pharmacokinetic properties may be preferred in this group. Women of childbearing age face specific problems related to the epilepsy and to treatment with anticonvulsants. These include impaired fertility, failure of oral contraceptives and the risk of birth defects. Some new anticonvulsants may be suggested in preference to classical drugs to avoid these problems, but the human experience with newer anticonvulsants is still limited and, therefore, so is knowledge of the risk of congenital malformations in the offspring of mothers taking anticonvulsants. Psychiatric and behavioural changes frequently complicate treatment of patients with mental retardation. Some of the new anticonvulsants, in particular those affecting the gamma-aminobutyric acid (GABA) system such as vigabatrin, seem to exacerbate this problem and should be used with caution in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.